Claims

1. A pharmaceutical composition in solid oral dosage form comprising 0.01 to 15% (w/w) of (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one and one or more pharmaceutically acceptable excipients, wherein (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one is in acetate salt form.

2. A pharmaceutical composition according to claim 1, comprising 0.01 to 5% (w/w) of (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one.

3. A pharmaceutical composition according to claim 1 or 2, comprising 0.1 to 1% (w/w) of (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one.

4. A pharmaceutical composition according to any of the preceding claims which is in the form of a tablet or a capsule.

5. Pharmaceutical composition according to any of the preceding claims, wherein the one or more excipients is selected from filler, lubricant, glidant, disintegrant and binder.

6. Pharmaceutical composition according to claim 5, wherein the filler is present in an amount of 15-90% (w/w).

7. Pharmaceutical composition according to claim 5 or 6, wherein the lubricant is present in an amount of 0.1-1% (w/w).

8. Pharmaceutical composition according to any of claims 5 to 7, wherein the glidant is present in an amount of 0.1-1% (w/w).

9. Pharmaceutical composition according to any of claims 5 to 8, wherein the binder is present in an amount of 1-20% (w/w).

10. Pharmaceutical composition according to any of claims 5 to 9, wherein the disintegrant is present in an amount of 1-20% (w/w).

11. A method for the manufacture of a pharmaceutical composition suitable for oral administration comprising (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one comprising the steps of

a) mixing (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one acetate salt with a filler and a glidant to form a pre-mix;

b) mixing the pre-mix obtained in step a) with a further filler and a disintegrant to obtain a powder;

c) adding a lubricant to the powder obtained in step b) to obtain a final blend; and

d) processing the final blend obtained in step c) into a pharmaceutical composition suitable for oral administration.

12. A method according to claim 11, wherein (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one acetate salt is used in an amount sufficient to provide 0.01-15% (w/w) (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one in the pharmaceutical composition.

13. A pharmaceutical composition in solid oral dosage form comprising 0.01 to 15% (w/w) of (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one and one or more pharmaceutically acceptable excipients, wherein (R)-7-(2-(1-(4-butoxyphenyl)-2-methylpropan-2-ylamino)-1-hydroxyethyl)-5-hydroxybenzo[d]thiazol-2(3H)-one is in acetate salt form, for use as a medicament.